Back to Search Start Over

Genital Abnormalities, Hormonal Contraception, and Human Immunodeficiency Virus Transmission Risk in Rwandan Serodifferent Couples.

Authors :
Wall, Kristin M
Karita, Etienne
Nyombayire, Julien
Ingabire, Rosine
Mukamuyango, Jeannine
Parker, Rachel
Brill, Ilene
Price, Matt
Haddad, Lisa B
Tichacek, Amanda
Hunter, Eric
Allen, Susan
Source :
Journal of Infectious Diseases; Jul2021, Vol. 224 Issue 1, p81-91, 11p
Publication Year :
2021

Abstract

<bold>Background: </bold>We explored the role of genital abnormalities and hormonal contraception in human immunodeficiency virus (HIV) transmission among heterosexual serodifferent couples in Rwanda.<bold>Methods: </bold>From 2002 to 2011, HIV-serodifferent couples who were not using antiretroviral treatment were followed up, and sociodemographic and clinical data were collected, family planning provided, and HIV-negative partners retested. Couples were assessed for genital ulcers; nonulcerative genital sexually transmitted infection (STIs), including gonorrhea, chlamydia, and trichomoniasis; and non-STI vaginal infections, including bacterial vaginosis and candida. Multivariable models evaluated associations between covariates and HIV transmission genetically linked to the index partner.<bold>Results: </bold>Among 877 couples in which the man was HIV positive, 37 linked transmissions occurred. Factors associated with women's HIV acquisition included genital ulceration in the female partner (adjusted hazard ratio, 14.1) and nonulcerative STI in the male partner (8.6). Among 955 couples in which the woman was HIV positive, 46 linked transmissions occurred. Factors associated with HIV acquisition in men included nonulcerative STI in the female partner (adjusted hazard ratio, 4.4), non-STI vaginal dysbiosis (7.1), and genital ulceration in the male partner (2.6). Hormonal contraception use was not associated with HIV transmission or acquisition.<bold>Conclusions: </bold>Our findings underscore the need for integrating HIV services with care for genital abnormalities. Barriers (eg, cost of training, demand creation, advocacy, and client education; provider time; and clinic space) to joint HIV/STI testing need to be considered and addressed. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00221899
Volume :
224
Issue :
1
Database :
Complementary Index
Journal :
Journal of Infectious Diseases
Publication Type :
Academic Journal
Accession number :
151284664
Full Text :
https://doi.org/10.1093/infdis/jiab071